FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015472310> ?p ?o ?g. }

• W2015472310 endingPage "CMO.S15172" @default.
• W2015472310 startingPage "CMO.S15172" @default.
• W2015472310 abstract "Background Patients with advanced non-small cell lung cancer (NSCLC) have no curative treatment options; therefore, improving their quality of life (QOL) is an important goal. Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, is a safe oral agent that may be of benefit to a specific population of NSCLC. Patients and Methods A Phase II clinical trial included chemonaïve patients with advanced NSCLC and poor performance status (PS). Response rate, progression-free survival, overall survival, QOL using the Functional Assessment of Cancer Therapy – Lung (FACT-L) questionnaire, and Trial Outcome Index (TOI) were evaluated. Results Twelve out of 19 enrolled patients were evaluable. The median age for the evaluable patients was 68.8 years (59.7–74.6). Out of all the patients, 7 (58.3%) had adenocarcinoma and 5 (41.7%) had squamous cell carcinoma. The median duration of treatment was 62.5 days (26.5–115.0) in the evaluable patients. Grade 3/4 toxicities included fatigue, rash, diarrhea, and nausea. One patient had partial response, eight patients had stable disease (SD), and three patients progressed. The median overall survival for the evaluable population was 4.9 months (2.3–16). The median progression-free survival was 3.7 months (1.9–6.6). TOI was marginally associated with the overall survival, with a hazard ratio of 0.92 (95% confidence interval: 0.84, 1.0) ( P = 0.061). FACT-L score and the TOI were highly correlated ( r = 0.96, P < 0.0001). TOI scores were higher in African Americans compared to Caucasians and increased with age. Conclusion Our results suggest that gefitinib use in patients with NSCLC and poor PS may improve the QOL of older patients and African American patients." @default.
• W2015472310 created "2016-06-24" @default.
• W2015472310 creator A5036949233 @default.
• W2015472310 creator A5043735279 @default.
• W2015472310 creator A5057093016 @default.
• W2015472310 creator A5064251341 @default.
• W2015472310 creator A5091340075 @default.
• W2015472310 date "2014-01-01" @default.
• W2015472310 modified "2023-09-28" @default.
• W2015472310 title "Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status" @default.
• W2015472310 cites W1966713566 @default.
• W2015472310 cites W1967994295 @default.
• W2015472310 cites W1977833366 @default.
• W2015472310 cites W1995002313 @default.
• W2015472310 cites W2005779868 @default.
• W2015472310 cites W2005925676 @default.
• W2015472310 cites W2014725195 @default.
• W2015472310 cites W2014785602 @default.
• W2015472310 cites W2019236425 @default.
• W2015472310 cites W2029161282 @default.
• W2015472310 cites W2035328604 @default.
• W2015472310 cites W2036449282 @default.
• W2015472310 cites W2068689938 @default.
• W2015472310 cites W2070646956 @default.
• W2015472310 cites W2084800358 @default.
• W2015472310 cites W2111191667 @default.
• W2015472310 cites W2117626696 @default.
• W2015472310 cites W2120718661 @default.
• W2015472310 cites W2129274454 @default.
• W2015472310 cites W2129360604 @default.
• W2015472310 cites W2130177644 @default.
• W2015472310 cites W2132157071 @default.
• W2015472310 cites W2136228097 @default.
• W2015472310 cites W2139343412 @default.
• W2015472310 cites W2146404049 @default.
• W2015472310 cites W2148484849 @default.
• W2015472310 cites W2153477391 @default.
• W2015472310 cites W2161817637 @default.
• W2015472310 cites W2168431047 @default.
• W2015472310 cites W2249538727 @default.
• W2015472310 cites W2291356857 @default.
• W2015472310 cites W2416211740 @default.
• W2015472310 doi "https://doi.org/10.4137/cmo.s15172" @default.
• W2015472310 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4245085" @default.
• W2015472310 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25520566" @default.
• W2015472310 hasPublicationYear "2014" @default.
• W2015472310 type Work @default.
• W2015472310 sameAs 2015472310 @default.
• W2015472310 citedByCount "3" @default.
• W2015472310 countsByYear W20154723102016 @default.
• W2015472310 countsByYear W20154723102018 @default.
• W2015472310 countsByYear W20154723102020 @default.
• W2015472310 crossrefType "journal-article" @default.
• W2015472310 hasAuthorship W2015472310A5036949233 @default.
• W2015472310 hasAuthorship W2015472310A5043735279 @default.
• W2015472310 hasAuthorship W2015472310A5057093016 @default.
• W2015472310 hasAuthorship W2015472310A5064251341 @default.
• W2015472310 hasAuthorship W2015472310A5091340075 @default.
• W2015472310 hasBestOaLocation W20154723101 @default.
• W2015472310 hasConcept C121608353 @default.
• W2015472310 hasConcept C126322002 @default.
• W2015472310 hasConcept C141071460 @default.
• W2015472310 hasConcept C143998085 @default.
• W2015472310 hasConcept C207103383 @default.
• W2015472310 hasConcept C2776256026 @default.
• W2015472310 hasConcept C2776907518 @default.
• W2015472310 hasConcept C2778570526 @default.
• W2015472310 hasConcept C2779438470 @default.
• W2015472310 hasConcept C2780580376 @default.
• W2015472310 hasConcept C2780580887 @default.
• W2015472310 hasConcept C2908647359 @default.
• W2015472310 hasConcept C44249647 @default.
• W2015472310 hasConcept C71924100 @default.
• W2015472310 hasConcept C90924648 @default.
• W2015472310 hasConcept C99454951 @default.
• W2015472310 hasConceptScore W2015472310C121608353 @default.
• W2015472310 hasConceptScore W2015472310C126322002 @default.
• W2015472310 hasConceptScore W2015472310C141071460 @default.
• W2015472310 hasConceptScore W2015472310C143998085 @default.
• W2015472310 hasConceptScore W2015472310C207103383 @default.
• W2015472310 hasConceptScore W2015472310C2776256026 @default.
• W2015472310 hasConceptScore W2015472310C2776907518 @default.
• W2015472310 hasConceptScore W2015472310C2778570526 @default.
• W2015472310 hasConceptScore W2015472310C2779438470 @default.
• W2015472310 hasConceptScore W2015472310C2780580376 @default.
• W2015472310 hasConceptScore W2015472310C2780580887 @default.
• W2015472310 hasConceptScore W2015472310C2908647359 @default.
• W2015472310 hasConceptScore W2015472310C44249647 @default.
• W2015472310 hasConceptScore W2015472310C71924100 @default.
• W2015472310 hasConceptScore W2015472310C90924648 @default.
• W2015472310 hasConceptScore W2015472310C99454951 @default.
• W2015472310 hasLocation W20154723101 @default.
• W2015472310 hasLocation W20154723102 @default.
• W2015472310 hasLocation W20154723103 @default.
• W2015472310 hasLocation W20154723104 @default.
• W2015472310 hasLocation W20154723105 @default.
• W2015472310 hasOpenAccess W2015472310 @default.
• W2015472310 hasPrimaryLocation W20154723101 @default.

• next